As a leader in the field of lysibody research, Creative Biolabs is committed to providing a one-stop testing service for the development of lysibody-based vaccines. Our vision is to help our clients worldwide achieve great success in this field.
Therapeutic antibodies and vaccines represent promising treatment alternatives for antibiotic-resistant pathogens. Cell wall carbohydrates are attractive alternative targets for the development of therapeutic antibodies, with several advantages over traditional protein targets. Wall carbohydrates are vital elements of bacterial cell walls and are closely related to maintaining the structure and function of bacterial cell envelopes. Furthermore, these molecules are highly conserved within species. However, the production of conventional therapeutic antibodies for carbohydrates is complicated by their very low immunogenicity. Combining specific carbohydrates with carrier proteins for immunization offers a viable solution. However, generating effective opsonizing antibodies against carbohydrates remains difficult.
Currently, several polysaccharide-protein conjugate vaccines have attracted considerable attention because they elicit only humoral immunity against protein-associated microbial carbohydrate antigens. Studies suggest antibody-based vaccine strategies may be effective against intracellular pathogens. The success of this conjugate vaccine paves the way for the development of other vaccines targeting intracellular pathogens.
Creative Biolabs is committed to providing diverse services. Our services include but are not limited to:
Lysibodies are engineered molecules that integrate a phage-derived carbohydrate-binding domain and the Fc effector portion of a human immunoglobulin G (IgG) antibody to direct efficient immunity against conserved bacterial surface carbohydrates. Lysibodies are considered to be homodimeric hybrid IgG molecules that behave like true IgG that can bind with high affinity to their bacterial wall receptors. Our lysibody construction services allow the lysibody-based vaccines to solve the long-standing problem of efficiently targeting bacterial surface carbohydrates with antibodies.
At Creative Biolabs, various in vitro assays are used to characterize the validity of lysibodies and their ability to bind to specific bacterial cell walls. In addition, we also performed different experiments to characterize the ability of different lysibodies to induce macrophage and neutrophil phagocytosis of Staphylococcus. We perform experimental analysis using a combination of techniques such as fluorescence microscopy, enzyme-linked immunosorbent assay (ELISA), and flow cytometry.
Many animal models are available at Creative Biolabs. Our animal models are critical for testing the pharmacokinetics, immunogenicity, and toxicity of lysins. In addition, animal models are closely related to vaccine efficacy and safety testing. In conclusion, our animal model provides a promising platform for the development of lysibody-based vaccines. Our services including:
As a reputable global service provider, Creative Biolabs has extensive experience in lysibodies and vaccine development. Our dedicated scientists are confident to customize a reasonable plan according to your unique needs to help you achieve great breakthroughs in the development of lysibody-based vaccines. Please contact us promptly to know how we assist your project.
* For Research Use Only. We do not provide direct services or products for patients.